第三代络酪氨酸蛋白激酶缓聚剂奥希替尼可做为肺癌的一线医治药品

  • A+
所属分类:医疗资讯

第三代络酪氨酸蛋白激酶缓聚剂奥希替尼可做为肺癌的一线医治药品 。
摘 要:奥希替尼生产商。第三代络酪氨酸蛋白激酶缓聚剂奥希替尼可做为肺癌的一线医治药品英国《临床肿瘤杂志》2022年8月25日线上先给http://ascopubs.org/doi/abs/10.1200/JCO.2017.74.7576

奥希替尼做为EGFR基因突变呈阳性晚中后期非小细胞肺癌的一线医治

目地“病患者初次用奥希替尼的使用量增长科学研究(AURA)”(ClinicalTrials.gov网址许可证号:NCT01802632)列入了2个初治病患者序列,以掌握奥希替尼(一种外皮细胞生长因子蛋白激酶[EGFR]络酪氨酸蛋白激酶缓聚剂,可选择性用以EGFR络酪氨酸蛋白激酶缓聚剂比较敏感基因突变[EGFRm]和EGFR T790M承受药品基因突变)做为EGFR基因突变晚中后期非小细胞肺癌一线医治的临床医学实效性和安全防护特点。病患者与方式 60名部分晚中后期或迁移扩散性的EGFR络酪氨酸蛋白激酶缓聚剂比较敏感基因突变[EGFRm]的非小细胞肺癌初治病患者,接纳吉非替尼医治,每日内服80mg或160mg(每一组30名)。终点站包含科学研究工作人员点评的客观缓解率(ORR)、无进度存活第三代络酪氨酸蛋白激酶缓聚剂奥希替尼可做为肺癌的一线医治药品時间(PFS)及其安全性特点点评。病患者病症进度时或进度后收集血液标本采集,以科学研究奥希替尼承受药品体制,病症进度依照“实体肿瘤治疗效果点评规范(RECIST)”开展明确。結果在数据信息锁住日(2016年11月1日),负相关随诊的时间为19.一个月,80mg组总的客观缓解率为67%(95%CI,47%-83%)、160mg组为87%(95%CI,69%-96%)、使用量归纳后的总的客观缓解率为77%(95%CI,64%-87%),80mg组负相关无进度存活時间22.一个月(95%CI,13.7-30.2个月)、160mg组19.3个月(95%CI,13.7-26.0个月)、使用量归纳后的负相关无进度存活時间20.5个月(95%CI,15.0-26.1)。进度后收集了血液标本采集的38名病患者中,50%的病患者查验到循环系统恶性肿瘤DNA,19名中有9名存有很有可能的承受药品体制,包含MET增加(n=1)、EGFR和KRAS增加(n=1)、MEK1和KRAS或PIK3CA基因突变(n=1,各一名)、EGFR C797S基因突变(n=2)、JAK2基因突变(n=1)、HER2外显子20插进(n=1),未查验到继发性EGFR T790M基因突变。结果在EGFRm基因突变的晚中后期非小细胞肺癌初治病患者中,奥希替尼大幅度提高了客观缓解率、提升了无进度存活時间。在进度后收集的血液样本中未发觉继发性EGFR T790M基因突变。南南和晨晨

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

PurposeThe Osimertinib First Time in Patients Ascending Dose (AURA) study (ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] –tyrosine kinase inhibitor selective for EGFR–tyrosine kinase inhibitor sensitizing [EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC).Patients and MethodsSixty treatment-naïve patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort). End points included investigator-assessed objective response rate (ORR), progression-free survival (PFS), and safety evaluation. Plasma samples were collected at or after patients experienced disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), to investigate osimertinib r第三代络酪氨酸蛋白激酶缓聚剂奥希替尼可做为肺癌的一线医治药品esistance mechanisms.ResultsAt data cutoff (November 1, 2016), median follow-up was 19.1 months. Overall ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses. Median PFS time was 22.1 months (95% CI, 13.7 to 30.2 months) in the 80-mg group, 19.3 months (95% CI, 13.7 to 26.0 months) in the 160-mg group, and 20.5 months (95% CI, 15.0 to 26.1 months) across doses. Of 38 patients with postprogression plasma samples, 50% had no detectable circulating tumor DNA. Nine of 19 patients had putative resistance mechanisms, including amplification of MET (n = 1); amplification of EGFR and KRAS (n = 1); MEK1, KRAS, or PIK3CA mutation (n = 1 each); EGFR C797S mutation (n = 2); JAK2 mutation (n = 1); and HER2 exon 20 insertion (n = 1). Acquired EGFR T790M was not detected.ConclusionOsimertinib demonstrated a robust ORR and prolonged PFS in treatment-naïve patients with EGFRm advanced NSCLC. There was no evidence of acquired EGFR T790M mutation in postprogression plasma samples.《壹篇》(与桓兴医讯同歩)系关键朝向医护人员的服务性【微信号码:yaodaoyaofang】,不因盈利为目地,不开展一切有偿服务资询和服务项目,不销售一切商品,与ASCO、CSCO等全部技术专业学好和组织并没有任何的关联和联络,都不意味着一切官方网学好发音。文章照片均来源于互联网,不做商业行为,若有著作权异议请与《壹篇》联络。不断关注点赞——【手机微信:india2080】、称赞和分享——【手机微信:india2080】是一种心态和适用。
药道精确防癌-助推性命。印度的全世界海淘药店:埃克替尼 奥希替尼。

  • 微信咨询
  • 这是我的微信扫一扫
  • weinxin
  • WhatsApp 沟通
  • 手机扫一扫二维码
  • weinxin

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: